MAIA Biotechnology Inc (MAIA)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.32-0.75%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MAIA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MAIA — M&A activity — Termination
Dated 2026-05-14
Termination of a Material Definitive Agreement. On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination wi…
Why it matters: High losses could mean financial trouble. Improvement would show better cost control.
Worry ifOperating losses are going down a lot. This shows better cost control.
Less concerning ifOperating losses are still high or rising. This shows worsening financial health.
Why it matters: Financial results will show if MAIA is controlling cash burn well. This impacts investor confidence.
Worry ifOperating losses decrease from -$8.3M in 2026-Q2 to below -$6M.
Less concerning ifOperating losses increase past -$8.3M. This shows poor financial management.
Why it matters: Good survival data may prove ateganosine works. This could bring in more money.
Supportive ifThe survival data shows over 24 months for many patients.
Worry ifOverall survival data does not meet or exceed 24 months for patients.
Why it matters: Ending this could hurt MAIA's chances to raise money. This may affect their stability.
Worry ifManagement says the end of the agreement won't stop future funding plans.
Less concerning ifManagement says ending the ATM sales deal will hurt funding.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$228 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $779 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,932 loss on $10,000 · 59.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This offering is important for MAIA. It will help raise money and support operations.
Supportive ifThe company finishes the public offering. It raises the planned amount of money.
Worry ifThe offering does not close. It raises much less money than expected.
Why it matters: The termination could affect MAIA's ability to raise funds and manage cash flow.
Worry ifMAIA gives clear plans for raising money after the termination.
Less concerning ifMAIA still has problems raising money after the termination.
Why it matters: This could impact MAIA's ability to raise funds and manage cash flow.
Watch forThe company shares a new plan. This plan will replace the ended ATM sales agreement.
Also watch forNo new funding strategy is announced, and cash flow issues persist.
Why it matters: Interim data could support early discussions with the FDA for full approval. This would show the drug's potential in treating NSCLC.
Supportive ifInterim data from the Phase 3 trial shows efficacy consistent with Phase 2 results.
Worry ifEarly data shows less effectiveness than what was found in Phase 2 trials.
Why it matters: More sites would expand patient access and data collection for the THIO-101 trial. This is crucial for understanding the drug's effectiveness.
Supportive ifMAIA activates four additional U.S. clinical sites for the THIO-101 trial.
Worry ifNo new U.S. sites are activated for the THIO-101 trial by the end of 2026.
Why it matters: Updates on funding could indicate the financial health of MAIA and its ability to complete the trial. This affects investor confidence.
Watch forManagement confirms that the $33 million capital raise fully funds the Phase 3 trial.
Also watch forManagement announces funding shortfalls or delays for the Phase 3 trial.